Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.

Dr. Brendan M. O'Malley J.D., Ph.D.

Senior Vice President & General Counsel

Mr. Brian  Kevany Ph.D.

Senior Vice President, Chief Technology Officer & CSO

Dr. Madhav  Vasanthavada M.B.A., Ph.D.

Senior Vice President, Chief Commercial Officer & Head of Business Development

Mr. Carl  Denny

Senior Vice President of Regulatory Affairs

Dr. Vishwas  Seshadri M.B.A., Ph.D.

President, Chief Executive Officer & Director

Mr. Jon  Voss

Vice President & Head of Quality

Mr. Gregory  Gin

Vice President of Investor Relations & Corporate Communications

Mr. Dmitriy  Grachev M.D., Ph.D.

Chief Medical Officer

Ms. Alison  Hardgrove

Vice President of Human Resources

Βιοτεχνολογία

Abeona Therapeutics Inc.

Abeona Therapeutics Inc. Δομή της διοίκησης

Πληροφορίες για τη διοίκηση